ArticleClinical trials (London, England)2026
A note on rank-preserving structural failure time models to account for crossover.
Article in Clinical trials (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Treatment switching in oncology evidence synthesis: a systematic review of meta-analytical practices incorporating time-dependent confounding, censoring bias, and patient-level variability.Dialogues in health · 2026Article
- Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma.Blood cancer discovery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundIn randomized trials where some standard-treatment arm patients cross to the experimental treatment, it is frequently of interest to estimate the between-arm survival difference as if no patients on the standard-treatment arm had crossed over to the experimental treatment. Rank-preserving structural failure time models, an extension of semiparametric accelerated-failure-time models, are a popular method for accomplishing this because they do not require modeling which patients will crossover.
methodsIn trying to apply the rank-preserving structural failure time model in practice, we noted some unusual behavior of the estimated acceleration parameter (differential treatment effect). Simple examples and limited simulations are provided to examine and understand this behavior.
resultsThe simulations show that rank-preserving structural failure time model estimator of the acceleration parameter can take on extreme values, especially when the intent-to-treat analysis favors the standard-treatment arm. Furthermore, the addition of censoring is paradoxically shown to reduce the estimator's variability compared to the uncensored data when the underlying observations are exponentially distributed. Use of a Weibull distribution with short tails for the survival times eliminates this unusual behavior.
conclusionThe rank-preserving structural failure time model estimators of the acceleration parameter are not based on the joint ranks of the original data, and it is suggested that this makes acceleration-parameter estimator unstable with long-tailed survival distributions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.